Metabolic inhibitors and intermediate filament organization in human fibroblasts.
A number of metabolic inhibitors including the mRNA transcription inhibitor actinomycin D; the protein synthesis inhibitors emetine, cycloheximide, and puromycin; the energy metabolism inhibitors sodium azide and oligomycin; the amino acid analog L-azetidine-2-carboxylic acid; sodium fluoride; and acrylamide each cause the collapse of vimentin filament organization while leaving microtubule organization apparently unaffected in the human fibroblastic cell line MCH23. The protein kinase inhibitor N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (H8) caused a partial collapse of vimentin organization but its effect was more difficult to discern, since it also induced a dramatic change in cellular morphology. Each of these drugs produced a significant inhibition of protein synthesis at concentrations that affected vimentin organization. The mechanisms by which these drugs affect intermediate filament organization are unclear, but our results demonstrate that intermediate filament organization in MCH23 cells is affected by a wide range of drugs and that such drugs cannot be used without great caution as reagents for the study of intermediate filament organization and function.
Klymkowsky
M W
MW
Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder 80309-0347.
D020106:Acrylamide; D000178:Acrylamides / Q000494:pharmacology; D001386:Azides / Q000494:pharmacology; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D003599:Cytoskeleton / Q000648:ultrastructure*; D003609:Dactinomycin / Q000494:pharmacology; D004640:Emetine / Q000494:pharmacology; D005347:Fibroblasts / Q000187:drug effects / Q000648:ultrastructure; D005455:Fluorescent Antibody Technique; D006801:Humans; D007382:Intermediate Filaments / Q000187:drug effects / Q000648:ultrastructure*; D008297:Male; D008870:Microtubules / Q000187:drug effects / Q000648:ultrastructure; D009840:Oligomycins / Q000494:pharmacology; D011691:Puromycin / Q000494:pharmacology; D012867:Skin; D019810:Sodium Azide; D012969:Sodium Fluoride / Q000494:pharmacology; D014746:Vimentin / Q000378:metabolism
D000178:Acrylamides; D001386:Azides; D009840:Oligomycins; D014746:Vimentin; D003609:Dactinomycin; D020106:Acrylamide; D011691:Puromycin; D012969:Sodium Fluoride; D019810:Sodium Azide; D003513:Cycloheximide; D004640:Emetine